Acquisition Completed

Fresenius acquisition of mAbxience

€1.7bn equity value

Announced Oct 2026 (approx.)

Advisers

mAbxience

Target

Not disclosed

Fresenius

Acquirer

Financial adviser
Target
mAbxience
Acquirer
Fresenius
Target based in
Spain
Buyer based in
Germany
Completed
1 Oct 2026
Stake
45%
Sector
Biotech
Tags
Biotech, Pharma

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.